Complement activation in experimental human malaria infection
- PMID: 17481680
- DOI: 10.1016/j.trstmh.2007.02.023
Complement activation in experimental human malaria infection
Abstract
The objective of this study was to investigate complement activation in uncomplicated, early phases of human malaria. Fifteen healthy volunteers were experimentally infected with Plasmodium falciparum malaria. Parasitemia and complement activation products were assessed. During blood stage parasitemia, volunteers showed a significant increase in soluble terminal complement complex (TCC) formation. After start of a curative regimen of artemether/lumefantrine, TCC further increased due to activation of both the classical and the alternative pathway. In-vitro studies confirmed activation of complement by parasite cultures. We thus detected an increase in complement activation in volunteers with experimentally induced malaria, even before parasitemia could be detected microscopically. This significant increase in complement activation occurred despite the possible control of TCC formation by complement regulatory proteins on erythrocytes and the extremely low levels of parasitemia. Treatment with artemether/lumefantrine was followed by classical and alternative pathway complement activation, without evidence for mannan-binding-lectin-mediated complement activation.
Similar articles
-
Treatment of acute uncomplicated falciparum malaria with artemether-lumefantrine in nonimmune populations: a safety, efficacy, and pharmacokinetic study.Am J Trop Med Hyg. 2008 Feb;78(2):241-7. Am J Trop Med Hyg. 2008. PMID: 18256423 Clinical Trial.
-
Therapeutic efficacy of artemether-lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria in Bangladesh.Am J Trop Med Hyg. 2007 Jan;76(1):39-41. Am J Trop Med Hyg. 2007. PMID: 17255226 Clinical Trial.
-
Adherence and efficacy of supervised versus non-supervised treatment with artemether/lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria in Bangladesh: a randomised controlled trial.Trans R Soc Trop Med Hyg. 2008 Sep;102(9):861-7. doi: 10.1016/j.trstmh.2008.05.022. Epub 2008 Jul 7. Trans R Soc Trop Med Hyg. 2008. PMID: 18606428 Clinical Trial.
-
Artemether-lumefantrine: an oral antimalarial for uncomplicated malaria in children.Expert Rev Anti Infect Ther. 2009 Aug;7(6):669-81. doi: 10.1586/eri.09.53. Expert Rev Anti Infect Ther. 2009. PMID: 19681693 Review.
-
[The terminal complement complex (TCC)--a mediator in the development of disease in man?].Ugeskr Laeger. 1991 Jan 28;153(5):351-3. Ugeskr Laeger. 1991. PMID: 1994560 Review. Danish.
Cited by
-
Genetic polymorphisms of mannose-binding lectin do not influence placental malaria but are associated with preterm deliveries.Infect Immun. 2009 Apr;77(4):1483-91. doi: 10.1128/IAI.01069-08. Epub 2009 Jan 12. Infect Immun. 2009. PMID: 19139195 Free PMC article.
-
Complement activation by merozoite antigens of Plasmodium falciparum.PLoS One. 2014 Aug 21;9(8):e105093. doi: 10.1371/journal.pone.0105093. eCollection 2014. PLoS One. 2014. PMID: 25144772 Free PMC article.
-
Human C1-Inhibitor Suppresses Malaria Parasite Invasion and Cytoadhesion via Binding to Parasite Glycosylphosphatidylinositol and Host Cell Receptors.J Infect Dis. 2016 Jan 1;213(1):80-9. doi: 10.1093/infdis/jiv439. Epub 2015 Sep 7. J Infect Dis. 2016. PMID: 26347576 Free PMC article.
-
C5a enhances dysregulated inflammatory and angiogenic responses to malaria in vitro: potential implications for placental malaria.PLoS One. 2009;4(3):e4953. doi: 10.1371/journal.pone.0004953. Epub 2009 Mar 24. PLoS One. 2009. PMID: 19308263 Free PMC article.
-
Increased deposition of C3b on red cells with low CR1 and CD55 in a malaria-endemic region of western Kenya: implications for the development of severe anemia.BMC Med. 2008 Aug 21;6:23. doi: 10.1186/1741-7015-6-23. BMC Med. 2008. PMID: 18717995 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources